Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

A.S. Michallet , M.S. Dilhuydy , F. Subtil , V. Rouille , B. Mahe , K. Laribi , B. Villemagne , G.A. Salles , O. Tournilhac (1) , A.J. Delmer , C. Portois , B. Pegourie , V. Leblond , C. Tomowiak , S. de Guibert , F. Orsini , A. Banos , P. Carassou , G. Cartron , L.M. Fornecker , Loic Ysebaert , C. Dartigeas , M. Truchan , J.P. Vilque , T. Aurran , F. Cymbalista , S. Lepretre , M.V. Levy , F. Nguyen-Khac , M. Le Garff-Tavernier , C. Aanaei , M. Ticchioni , R. Letestu , P. Feugier

1 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias

Domaines: Hématologie

A.S. Michallet, M.S. Dilhuydy, F. Subtil, V. Rouille, B. Mahe, et al.. Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial. 61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3038, 2019, Blood. ⟨hal-02427562⟩